MAPT and Alzheimer disease: In numerous cohorts, blood-based core AD biomarkers correlated highly with CSF AD biomarkers in all stages of AD.10 In addition to core AD biomarkers (decreased β-amyloid [Aβ] 42/40 ratio and increased phosphorylated-tau [P-tau] concentrations), other more general biomarkers including neurofilament light (NfL) as a marker for neuroaxonal damage and glial fibrillary acidic protein (GFAP) reflecting reactive astrogliosis are elevated in both patients with DLB and AD compared with HC.11, -, 13